IRC 004 - Comparing Tamiflu (Oseltamivir) Versus Placebo for the Treatment of Influenza in Low-Risk Adults
What is IRC 004? IRC 004 is a medical research study that aims to determine if treatment with oseltamivir (Tamiflu®) will show a decrease in the amount of the influenza (flu) virus detected in patients, and also to understand if the change in the amount of virus present is associated with changes in flu symptoms during the course of illness and treatment. Tamiflu® is licensed by the FDA to treat influenza and is recommended for use in patients who are at high risk of developing complications. Study-related medications and medical exams will be provided at no charge, and volunteers may be compensated for their time.
Who is eligible to volunteer for the study? Adults, at least 18 years old, who test positive for influenza and do not have a condition that increases their likelihood of developing complications of influenza (such as advanced age (65 years or older), asthma, diabetes, lung disease, heart disease, blood and/or kidney disorders, Body Mass Index (BMI) greater than 40).
How do I volunteer for the study? Please contact a participating research site in your area for more information if you:
- Start to experience any symptoms of influenza such as fever, cough, sore throat, stuffy or runny nose, sweats/chills, head or muscle aches
- Are an adult
- Do not have an existing medical condition that puts you at increased risk for complications from influenza
Please review the list of participating sites below and click on the site name for the address and phone number.
Additional information about this trial can be found on the ClinicalTrials.gov website, under the title: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults